Syndax Pharmaceuticals KUV 2024

Syndax Pharmaceuticals Aktienanalyse

Šta radi Syndax Pharmaceuticals?

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

KUV у детаљу

Otključavanje KUV-a kompanije Syndax Pharmaceuticals

Koeficijent cene i prometa (KUV) kompanije Syndax Pharmaceuticals je važan finansijski pokazatelj koji meri tržišnu vrednost kompanije u odnosu na njen ukupni prihod od prodaje. Izračunava se deljenjem tržišne kapitalizacije kompanije sa njenim ukupnim prihodom od prodaje za određeni vremenski period. Niži KUV može ukazivati na to da je kompanija podcenjena, dok viši koeficijent može ukazivati na prekomernu vrednost.

Godišnja poređenja KUV-a

Poređenje KUV-a kompanije Syndax Pharmaceuticals na godišnjem nivou pruža uvid u to kako tržište percipira vrednost kompanije u odnosu na njene prodaje. Rastući koeficijent tokom vremena može ukazivati na rastuće poverenje investitora, dok opadajući trend može odražavati zabrinutost u vezi sposobnosti generisanja prihoda kompanije ili tržišnih uslova.

Utjecaj na investicije

KUV je ključan za investitore prilikom procene akcija kompanije Syndax Pharmaceuticals. Pruža uvid u efikasnost kompanije u generisanju prihoda i njenom tržišnom vrednovanju. Investitori koriste ovaj koeficijent za poređenje sličnih kompanija unutar iste industrije, i pomaže u izboru akcija koje nude najbolju vrednost za investiciju.

Interpretacija fluktuacija KUV-a

Promene u KUV-u kompanije Syndax Pharmaceuticals mogu proisteći iz promena u ceni akcija, prihodima od prodaje ili oboje. Razumevanje ovih fluktuacija je ključno za investitore za procenu trenutne vrednosti kompanije i potencijalnog budućeg rasta, te usmeravanje investicionih strategija u skladu s tim.

Često postavljana pitanja o Syndax Pharmaceuticals akciji

Koje je odnos cene i zarade akcija od Syndax Pharmaceuticals?

Odnos cene i dobiti akcija Syndax Pharmaceuticals trenutno iznosi 45,35.

Kako se odnos cene i zarade akcija Syndax Pharmaceuticals promenio u poređenju sa prošlom godinom?

Odnošaj cene i zarade kompanije Syndax Pharmaceuticals u poređenju sa prošlom godinom porastao je za 0% opao.

Koje posledice visok odnos cene i zarade ima za investitore?

Visok odnos cene i dobiti ukazuje na to da su akcije kompanije relativno skupe i da investitori možda ostvare manji prinos.

Šta znači nizak odnos cene i zarade?

Nisko odnos cene i zarade znači da je akcija kompanije relativno jeftina i investitori mogu potencijalno ostvariti viši prinos.

Da li je odnos cene i dobiti akcija kompanije Syndax Pharmaceuticals visok u poređenju sa drugim kompanijama?

Da, odnos cene i zarade (P/E) kompanije Syndax Pharmaceuticals je visok u poređenju sa drugim kompanijama.

Kako povećanje odnosa cene i zarade od Syndax Pharmaceuticals utiče na kompaniju?

Povećanje odnosa cena-dobit od Syndax Pharmaceuticals bi dovelo do veće tržišne kapitalizacije preduzeća, što bi pak dovelo do veće procene vrednosti preduzeća.

Kako smanjenje odnosa cene i zarade od Syndax Pharmaceuticals utiče na kompaniju?

Smanjenje odnosa cene i zarade od Syndax Pharmaceuticals dovelo bi do niže tržišne kapitalizacije kompanije, što bi zauzvrat dovelo do niže vrednosti preduzeća.

Koji su neki faktori koji utiču na odnos cene i zarade od Syndax Pharmaceuticals?

Neki faktori koji utiču na odnos cene i zarade Syndax Pharmaceuticals su rast kompanije, finansijska situacija kompanije, razvoj industrije i opšta ekonomska klima.

Kolika je dividenda koju isplaćuje Syndax Pharmaceuticals?

U poslednjih 12 meseci, Syndax Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Syndax Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Syndax Pharmaceuticals?

Dividendski prinos od Syndax Pharmaceuticals trenutno iznosi .

Kada Syndax Pharmaceuticals isplaćuje dividendu?

Syndax Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Syndax Pharmaceuticals?

Syndax Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Syndax Pharmaceuticals?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Syndax Pharmaceuticals?

Syndax Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Syndax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Syndax Pharmaceuticals od 4. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 4. 10. 2024..

Kada je Syndax Pharmaceuticals poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 4. 10. 2024..

Kolika je bila dividenda od Syndax Pharmaceuticals u godini 2023?

U godini 2023 kompanija Syndax Pharmaceuticals je isplatila 0 USD kao dividende.

U kojoj valuti Syndax Pharmaceuticals isplaćuje dividendu?

Dividende od Syndax Pharmaceuticals se isplaćuju u USD.